Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
N.E.E. 1/35 21 vs AFIRMELLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.
Prevention of pregnancy (FDA-approved)
Prevention of pregnancy (FDA-approved)
One tablet orally once daily for 21 days, followed by 7 days off.
One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.
Norethindrone: terminal half-life 7-8 hours; Ethinyl estradiol: terminal half-life 12-14 hours (with enterohepatic recycling). Clinically, steady state achieved after 5-7 days.
Terminal elimination half-life: 12–15 hours. Steady-state achieved within 5 days with Q12H dosing.
Ethinyl estradiol: primarily hepatic via CYP3A4, undergoes conjugation (glucuronidation and sulfation). Norethindrone: hepatic reduction and conjugation, also metabolized by CYP3A4. Both undergo enterohepatic recirculation.
Ethinyl estradiol undergoes first-pass metabolism in gut and liver via CYP3A4, with conjugation to sulfate and glucuronide. Levonorgestrel is metabolized primarily by CYP3A4 to reduced and hydroxylated metabolites, then conjugated.
Norethindrone (NET) and ethinyl estradiol (EE) are excreted primarily in urine (~50-60% as metabolites) and feces (~30-40% as metabolites); less than 1% excreted unchanged.
Renal: 50% as unchanged drug and metabolites; fecal: 40% as metabolites; biliary: ~10% as glucuronide conjugates.
Norethindrone: ~97% bound (albumin, SHBG); Ethinyl estradiol: ~98% bound (albumin).
~99% bound to serum albumin and sex hormone-binding globulin.
Norethindrone: Vd 4-5 L/kg; Ethinyl estradiol: Vd 3-4 L/kg; indicates extensive tissue distribution.
2.8 L/kg (apparent Vd), indicating extensive tissue distribution.
Oral: Norethindrone ~64%; Ethinyl estradiol ~45% (first-pass metabolism).
Oral: ~70% due to first-pass metabolism.
No dose adjustment required. Use with caution in severe impairment.
No dose adjustment required for mild to moderate renal impairment. Not recommended for use in end-stage renal disease.
Contraindicated in Child-Pugh Class B or C (moderate to severe hepatic impairment).
Contraindicated in acute hepatic disease or severe (Child-Pugh C) hepatic impairment. Use with caution in mild to moderate hepatic impairment; monitor liver function.
Not indicated in prepubertal children; use only after menarche per adult dosing.
Not indicated for use before menarche. Post-menarche: same as adult dosing (one tablet daily) based on adult clinical trials.
Not indicated for contraception postmenopausal; use lowest effective dose for hormone therapy if applicable.
Not indicated for use in postmenopausal women; no specific dose adjustment required in healthy elderly, but limited data available.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially >35 years) and with heavy smoking (>15 cigarettes/day). Women over 35 who smoke should not use this product.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age (especially in women over 35) and with heavy smoking (15+ cigarettes/day). Women who use combination hormonal contraceptives should be strongly advised not to smoke.
Increased risk of thromboembolic disorders (e.g., DVT, PE, stroke, MI),Cigarette smoking significantly increases cardiovascular risk (see boxed warning),Elevated blood pressure,Hepatic neoplasia (benign and malignant) reported with long-term use,Gallbladder disease,Carbohydrate and lipid metabolic effects (monitor in prediabetic/diabetic patients),Headache (including migraine), discontinue if new or worsening pattern,Bleeding irregularities (breakthrough bleeding, amenorrhea),Chloasma (may persist after discontinuation),Retinal thrombosis (discontinue if unexplained vision loss)
Thrombotic disorders (venous thromboembolism, stroke, myocardial infarction),Cigarette smoking (increases cardiovascular risk),Hypertension (especially in women with renal disease or migraines),Gallbladder disease,Hepatic neoplasia (benign and malignant),Carbohydrate and lipid metabolism effects,Ocular lesions (retinal thrombosis),Depressed mood or depression,Uterine bleeding irregularities,Reduced efficacy with hepatic enzyme inducers
Thrombophlebitis, venous thromboembolism (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (current or history),Estrogen-dependent neoplasia (current or history),Hepatic adenoma or carcinoma (current or history),Active liver disease or impaired hepatic function (including jaundice with prior pill use),Major surgery with prolonged immobilization,Hypersensitivity to any component of the product,Age >35 years and smoking
Thrombophlebitis or thromboembolic disorders (current or history),Cerebrovascular or coronary artery disease (current or history),Known or suspected breast cancer, endometrial cancer, or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior oral contraceptive use,Hepatic adenoma or carcinoma (current or history),Known or suspected pregnancy,Hypersensitivity to any component of the product,Heavy smoking (≥15 cigarettes/day) in women over 35
Avoid grapefruit and grapefruit juice during treatment due to potential increase in estrogen exposure and risk of adverse effects. No other significant food interactions reported.
Grapefruit juice may increase ethinyl estradiol levels; avoid large quantities. No significant food restrictions. Administer with food if GI upset occurs.
N. E. E. 1/35 21 (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects based on population data, but should not be used once pregnancy is confirmed. Second and third trimesters: Known risks include feminization of male fetus, cardiovascular and skeletal abnormalities, and potential for long-term effects on the child. Immediate discontinuation if pregnancy occurs.
Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defects). Second and third trimesters: increased risk of fetal growth restriction, preterm birth, and neonatal respiratory distress. Postnatal: possible long-term developmental effects.
Contraindicated in breastfeeding. Estrogen and progestins pass into breast milk; may reduce milk quantity and quality. Estrogen can suppress lactation. M/P ratio for norethindrone is approximately 0.5–1.0; for ethinyl estradiol, M/P ratio is about 0.2. Use postpartum only after breastfeeding is fully established and only if no alternative. Generally avoid.
Contraindicated during breastfeeding. Small amounts of ethinyl estradiol and norethindrone are excreted in breast milk; M/P ratio not well defined. Potential for adverse effects on infant (e.g., jaundice, breast enlargement). May reduce milk production and quality.
No dosing adjustments applicable as drug is contraindicated in pregnancy. If inadvertently used, discontinue immediately. Pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) are not relevant due to contraindication.
Contraindicated in pregnancy; no dose adjustment recommended. If exposure occurs, immediate discontinuation is required. No pharmacokinetic data support safe use; avoid use entirely.
N. E. E. 1/35 21 is a monophasic combined oral contraceptive containing 1 mg norethindrone and 35 mcg ethinyl estradiol. It can be used for cycle control and dysmenorrhea. Missed pill management: if one pill is missed, take it as soon as remembered; if two or more are missed, use backup contraception for 7 days. Consider potential drug interactions with rifampin, certain anticonvulsants, and St. John's Wort which may reduce efficacy.
Afirmelle (levonorgestrel/ethinyl estradiol) is a combined oral contraceptive. Counsel patients to take at the same time daily to maintain consistent hormone levels. Use back-up contraception if a dose is missed. Monitor for signs of thromboembolism, especially in smokers over 35. Advise that certain antibiotics (e.g., rifampin) and anticonvulsants (e.g., phenytoin) may reduce efficacy. Consider progestin-only pill if contraindications to estrogen exist.
Take one tablet daily at the same time each day for 21 days, then 7 days off.,If you miss a pill, take it as soon as you remember. If more than one pill is missed, use backup contraception.,This medication does not protect against sexually transmitted infections.,Common side effects include nausea, headache, breast tenderness, and breakthrough bleeding.,Smoking increases risk of serious cardiovascular side effects; avoid smoking, especially if over 35.,Report symptoms of blood clots such as leg pain/swelling, chest pain, or sudden shortness of breath.
Take one pill at the same time every day, even if you don't have sex.,If you miss a pill, follow the instructions in the package insert or ask your healthcare provider.,Use a backup method (like condoms) if you start late or miss pills.,This medication does not protect against HIV or other sexually transmitted infections.,Common side effects include nausea, breast tenderness, and breakthrough bleeding.,Seek medical help if you have symptoms of a blood clot: sudden chest pain, leg swelling, or shortness of breath.,Smoking while on this pill increases your risk of serious cardiovascular events.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about N.E.E. 1/35 21 vs AFIRMELLE, answered by our medical review team.
N.E.E. 1/35 21 is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive: ethinyl estradiol (estrogen) and norethindrone (progestin). Suppresses gonadotropin (FSH, LH) release via negative feedback, inhibiting ovulation; increases cervical mucus viscosity to impede sperm penetration; alters endometrial development to reduce implantation likelihood.. AFIRMELLE is a Combined Oral Contraceptive that works by Combination oral contraceptive containing ethinyl estradiol and levonorgestrel. Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial receptivity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between N.E.E. 1/35 21 and AFIRMELLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of N.E.E. 1/35 21 is: One tablet orally once daily for 21 days, followed by 7 days off.. The standard adult dose of AFIRMELLE is: One tablet (0.1 mg levonorgestrel, 0.02 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 days of placebo.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between N.E.E. 1/35 21 and AFIRMELLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. N.E.E. 1/35 21 is classified as Category C. N.E.E. 1/35 21 (norethindrone/ethinyl estradiol) is contraindicated in pregnancy. First trimester: No increased risk of major birth defects based on population data, but should not. AFIRMELLE is classified as Category C. Pregnancy category X. Contraindicated in pregnancy due to risk of fetal harm. First trimester: exposure associated with congenital anomalies (e.g., cardiovascular, neural tube defe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.